Surprisingly, anti-PD1 treatment did not confer any additional therapeutic benefit beyond the reduced tumor growth resulting from induced MMR deficiency in neuroblastoma tumors (Figures 3C and 3D). This evidence concerns the gene PDCD1 and neuroblastoma.